Patents by Inventor Janos Pitlik

Janos Pitlik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 8691758
    Abstract: The present invention relates to compounds of formula I or formula Ia or pharmaceutically acceptable salts thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
    Type: Grant
    Filed: May 15, 2006
    Date of Patent: April 8, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Shawn D. Britt, Kevin M. Cottrell, Robert B. Perni, Janos Pitlik
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20140031277
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: May 24, 2013
    Publication date: January 30, 2014
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Kevin M. Cottrell, John J. Court, David D. Deininger, Luc J. Farmer, Janos Pitlik, Robert B. Perni
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20140010784
    Abstract: The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Application
    Filed: May 29, 2013
    Publication date: January 9, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Luc J. Farmer, Janos Pitlik, Robert B. Perni, John H. van Drie, JR.
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 8536136
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: September 17, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David Deininger, John Court, Luc Farmer, Janos Pitlik, Kevin Cottrell, Robert B. Perni
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 8486989
    Abstract: The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: July 16, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Luc J. Farmer, Robert B. Perni, Janos Pitlik, John H. van Drie, Jr.
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20130116169
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: June 7, 2012
    Publication date: May 9, 2013
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. van Drie
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 8426359
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: April 23, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, Robert B. Perni, Janos Pitlik, Wayne C. Schairer
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 8217048
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: July 10, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. van Drie
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 8039623
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Grant
    Filed: March 9, 2007
    Date of Patent: October 18, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, Robert B. Perni, Janos Pitlik
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20110104115
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: June 28, 2010
    Publication date: May 5, 2011
    Applicant: VERTEX PHARMACEUTICALS INCOROPRATED
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. Van Drie
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 7906550
    Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
    Type: Grant
    Filed: February 6, 2008
    Date of Patent: March 15, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, John Maxwell, Robert B. Perni, Janos Pitlik
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20100330109
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: December 16, 2009
    Publication date: December 30, 2010
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Kevin M. Cottrell, John J. Court, David D. Deininger, Luc J. Farmer, Janos Pitlik, Robert B. Perni
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20100173851
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: June 3, 2009
    Publication date: July 8, 2010
    Inventors: Janos Pitlik, Kevin M. Cottrell, Luc J. Farmer, Robert B. Perni, Lawrence F. Courtney, John H. van Drie, Mark A. Murcko
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 7745444
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: June 29, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. van Drie
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 7683033
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Grant
    Filed: February 4, 2005
    Date of Patent: March 23, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, John J. Court, David D. Deininger, Luc J. Farmer, Janos Pitlik, Robert B. Permi
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20090291902
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
    Type: Application
    Filed: November 5, 2008
    Publication date: November 26, 2009
    Inventors: Kevin M. Cottrell, Robert B. Perni, Janos Pitlik, Wayne C. Schairer
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Publication number: 20080311079
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: April 10, 2008
    Publication date: December 18, 2008
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. van Drie
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20080125376
    Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
    Type: Application
    Filed: February 6, 2008
    Publication date: May 29, 2008
    Inventors: Kevin M. Cottrell, John Maxwell, Robert B. Perni, Janos Pitlik
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 7378422
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Grant
    Filed: September 7, 2004
    Date of Patent: May 27, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. van Drie
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 7365092
    Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: April 29, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, John Maxwell, Robert B. Perni, Janos Pitlik